Previous 10 |
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts. Winning Bounce/Lag Momentum Stocks fo...
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his 2% trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts. Winning Bounce/Lag Momentum Stocks...
Aeterna Zentaris (TSX:AEZS) (NASDAQ:AEZS) stock is having a spectacular run on the market lately with a gain of over 25% in the past two weeks. Why the climb? It likely has to do with the company announcing that it was exploring long term strategic options, including selling itself. In ...
AEterna Zentaris ( AEZS ) has achieved European approval for their adult growth hormone deficiency "GHD" drug Macrilen (macimorelin). Investors expected a subsequent partner announcement to market Macrilen throughout Europe. However, a recent press release announced that the board of dir...
Aeterna Zentaris (NASDAQ: AEZS ): Q4 GAAP EPS of -$0.31. More news on: Aeterna Zentaris Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
CHARLESTON, S.C., March 26, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the fourth quarter and year ended December 31, 2018. All Amounts are in U.S. Dollars Highlights Total revenue for fisc...
CHARLESTON, S.C., March 19, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) will announce its fourth quarter and year ended December 31, 2018 financial and operating results after market close on Tuesday, March 26, 2019. About Aeterna Zentaris Inc. Aeterna...
CHARLESTON, S.C., March 12, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) announced today that its board of directors has formed a special committee of independent directors (the “Special Committee”) to review strategic options available to Ae...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
2024-07-17 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...